Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $73.1652W HIGH $191.62
Volume
2.90 M
Value Traded
117.23 M
Short % Float
7.36%
-1.5%Week
-10.29%1 Month
+5.61%3 Month
+38.57%6 Month
+58.99%5 Year
+313.02%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
9.51 B
EPS (TTM)
-3.19
P/E Ratio
-
Ent. Value
9.23 B
Total Shares
58.97 M
Float Shares
56.64 M
Insiders
3.97%
Institutions
103.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
GKOS Catalyst Timeline
Dated clinical, regulatory and corporate events for Glaukos Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Glaukos Corporation
409Total events
4Upcoming
112Tier-1 (high impact)
2015 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseRO-104Corporate
Glaukos signs exclusive license agreement with RevOpsis to develop and commercialize RO-104
neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO)source ↗
▲Long Term DataEpioxaApprovedClinical Data
Three-year follow-up data show sustained 1.9 D Kmax improvement and visual acuity gains with favorable safety profile
keratoconussource ↗
▲Topline ReadoutEpioxaApprovedClinical Data
Positive three-year topline results from Phase 3 extension study GLK-202-03 of Epioxa in keratoconus
keratoconussource ↗
▲Trial CompletionEpioxaApprovedTrial
92% of study eyes completed the year 3 visit in GLK-202-03
keratoconussource ↗
●Timing GuidancePresentation
Glaukos expects to file Q2 2026 Form 10-Q on or before August 10, 2026
▲Enrollment CompleteGLK-321Trial
Completed patient enrollment in Phase 2 study of GLK-321
Demodex blepharitissource ↗
▲Enrollment CompleteTrial
Completion of patient enrollment in U.S. 510(k) pivotal study of PRESERFLO MicroShunt
primary open-angle glaucoma (POAG)source ↗
▲Product LaunchEpioxaApprovedPost-Market
Permanent J-code J2789 assigned for Epioxa, effective July 1, 2026
keratoconussource ↗
▲Quarterly UpdateCorporate
Glaukos reports Q2 2026 financial results with record net sales of $185.6 million
▲Enrollment CompleteGLK-321Trial
Completion of patient enrollment in Phase 2 study of GLK-321 for Demodex Blepharitis
Demodex Blepharitissource ↗
▲Enrollment CompleteTrial
Completed patient enrollment in Phase 3b study for iDose TRIO
Ocular Hypertension - Glaucomasource ↗
▲Topline ReadoutClinical Data
Initial results of Phase 2a clinical trial for iDose TREX show mean IOP reductions of 8.6-10.8 mmHg through Month 3
Ocular Hypertension - Glaucomasource ↗
▲Other Regulator MilestoneEpioxaApprovedEx-US Regulatory
Permanent J-code received for Epioxa
◆Oral PresentationPresentation
Multiple scientific abstracts presented at 2026 ASCRS Annual Meeting
▲First Patient DosediLutionTrial
Patient enrollment underway in Phase 2 clinical trial for Demodex blepharitis
Demodex Blepharitissource ↗
▲Enrollment CompleteGLK-401Trial
Patient enrollment complete in Phase 2a first-in-human clinical trial of IVT multi-kinase inhibitor
AMD, DME, RVOsource ↗
▲Trial InitiationTrial
Phase 3b study of iDose TRIO recently commenced
Ocular Hypertension - Glaucomasource ↗
▲Trial InitiationTrial
Phase 2 clinical trials for 3rd Gen iLink currently underway
Keratoconussource ↗
▲Trial InitiationTrial
Advancing Phase 2b/3 clinical program for iDose TREX
Ocular Hypertension - Glaucomasource ↗
●Trial InitiationTrial
Active PMA study for iStent infinite label expansion
Glaucoma (label expansion)source ↗
●Trial InitiationTrial
US active IDE study for PRESERFLO MicroShunt
Advanced-Refractory Glaucomasource ↗
▲Supplemental ApprovalFDA Decision
FDA approved NDA labeling supplement allowing re-administration of iDose TR
open-angle glaucoma or ocular hypertensionsource ↗
▲Supplemental ApprovalFDA Decision
FDA approves NDA labeling supplement allowing re-administration of iDose TR
open-angle glaucoma or ocular hypertensionsource ↗
▲FDA Filing AcceptedRegulatory Filing
FDA approval for re-administration of iDose TR
Ocular Hypertension - Glaucomasource ↗
◆Trial InitiationTrial
Commence Phase 2 trial for iLution Blepharitis by end of 2025
Demodex Blepharitissource ↗
●IND SubmissionIND
IND amendment filed December 2025 for iDose TRIO
Ocular Hypertension - Glaucomasource ↗
◆FDA ApprovalEpioxaApprovedFDA Decision
Epioxa (Epi-on) FDA approval expected by end of 2025
Keratoconussource ↗
▲FDA ApprovalEpioxaApprovedFDA Decision
FDA approval of Epioxa (Epi-on) for keratoconus
Keratoconussource ↗
●Oral PresentationPresentation
Glaukos management to participate in Wells Fargo Healthcare Conference
▲Quarterly UpdateCorporate
Glaukos reports Q2 2025 financial results with net sales of $124.1M
▲Product LaunchEpioxaApprovedPost-Market
Epioxa transition from Photrexa; commercial launch
keratoconussource ↗
◆Enrollment UpdateTrial
Advance enrollment in PMA pivotal trial for iStent infinite label expansion
Mild-to-Moderate Glaucomasource ↗
▲EU ApprovalEx-US Regulatory
EU regulatory approval and commercial launch of iStent infinite
Glaucomasource ↗
Past FDA Catalysts and PDUFA Decisions
How GKOS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-27 | Idose Tr (travoprost) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C45 / 100
Pipeline Score
$731M
Pipeline Value
Not rated
Valuation Signal
5
Drugs Scored
0.3x
rNPV / MCap
Top 27%
Small Cap(rank 178 of 658)
Percentile Rank
Glaukos Corporation carries a moderate pipeline score (45/100), with $1.1B risk-adjusted pipeline value, led by Test Article A in Progressive Keratoconus (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Article A Small moleculeCompletedNCT03442751 | Progressive Keratoconus | Phase 3 | COMPLETED | 201 | Aug 10, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every GKOS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| iDose TR | glaucoma | Phase 2b/3 | 2024-11-15 | mean tfa concentrations: 3 months 5, 6 months 3.7, 12 months 5.6, 15 months 2, 18 months 2.2, 21 months 3.8, 24 months 3.3; avg amount of travoprost remaining: 24 months 16; adverse events: periorbital fat atrophy Up to 70% incidence, conjunctival hyperemia 30%-50% incidence, corneal endothelial cell loss Very low or no incidence, iris color change ~20% incidenceRead More | Investor Presentation November 2024 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Navratil TomasOfficer (CHIEF DEVELOPMENT OFFICER) | Sell | -888 69,930 held | $163.93 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GKOS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.8 % (-11.1 %) | 20.96 M | 150.00 K | -14.29% ( -25.00 K) |
GKOS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GKOS ranks across every disease it competes in
Competitive Position is a premium feature
See how GKOS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGKOS News
GKOS▼ -6.3%on this news
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
Glaukos Corporation has entered into an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a novel tri-specific biologic. This biologic aims to treat retinal diseases, specifically targeting neovascular age-related macular degeneration and diabetic macula edema. The partnership highlights Glaukos's commitment to advancing innovative therapies in ophthalmology.
Read more →GKOS▼ -6.3%on this newsshared move
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
Glaukos Corporation has announced positive topline results from a Phase 3 extension study of Epioxa®, its innovative therapy for keratoconus. The study highlights the durability and visual outcomes of the treatment, indicating its potential effectiveness and safety for patients. This marks a significant advancement in the management of corneal disorders.
Read more →GKOS▲ +6.6%on this newsshared move
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
Glaukos Corporation is set to announce its third quarter 2026 financial results on October 28, 2026, after market close. The company specializes in treatments for glaucoma and other eye conditions. A conference call will follow the announcement, allowing management to discuss the results with investors.
Read more →GKOSGlaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
Glaukos Corporation has launched the 'Could it be KC?' campaign to raise awareness about keratoconus, a rare eye condition. The initiative, which features NBA Champion Stephen Curry, aims to improve recognition and early detection of the disease. The campaign will expand its activities further in 2027 to continue its educational efforts.
Read more →GKOSGlaukos Announces Participation in Wells Fargo Healthcare Conference
Glaukos Corporation announced its participation in the Wells Fargo Healthcare Conference scheduled for September 9, 2026. The event will take place in Boston, MA, and aims to provide insights into the company's innovative therapies for ophthalmic conditions. A live and archived webcast will be available for investors.
Read more →GKOSGlaukos Announces Second Quarter 2026 Financial Results
Glaukos Corporation reported impressive financial results for Q2 2026, achieving record net sales of $185.6 million. This marks a 50% increase compared to the same period last year. The company also noted a 49% rise in sales on a constant currency basis, highlighting its strong market position in ophthalmic therapies.
Read more →GKOSGlaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
Glaukos Corporation has announced the successful completion of patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO MicroShunt. This device is designed for adult patients suffering from primary open-angle glaucoma (POAG) who have not responded to previous treatments. The study aims to evaluate the effectiveness of this novel therapy.
Read more →GKOSGlaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
Glaukos Corporation plans to release its second quarter 2026 financial results on July 29, 2026, after market close. The company, known for its ophthalmic therapies, will hold a conference call to discuss the results at 1:30 p.m. PT. This event is anticipated by investors as a potential indicator of the company's performance.
Read more →GKOSGlaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
Glaukos has successfully completed patient enrollment for its Phase 2 study of GLK-321, aimed at treating Demodex blepharitis. This milestone marks a significant step in the development of potential new therapies for this condition. The study's progress reflects Glaukos' commitment to advancing eye care solutions.
Read more →GKOSGlaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation has announced its participation in upcoming investor conferences. The details regarding the specific conferences and the nature of their presentations have not been disclosed in the article. This participation may provide investors with insights into the company's future direction and performance.
Read more →GKOSDisclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are
The investor presentation from Glaukos Corporation (GKOS) outlines forward-looking statements regarding future activities and developments. The presentation emphasizes the company's commitment to innovation in chronic eye disease treatments, specifically their iDose TR and Epioxa therapies. However, management highlights several risks and uncertainties that could affect their operational outcomes and financial performance, including regulatory hurdles and manufacturing challenges. Glaukos continues to invest significantly in R&D, aiming to address unmet clinical needs in eye care.
Read more →GKOSGlaukos Announces First Quarter 2026 Financial Results
Glaukos Corporation reported record financial results for Q1 2026, with net sales reaching $150.6 million, a 41% increase from the previous year. The company raised its 2026 net sales guidance to between $620 million and $635 million. Despite the positive sales growth, Glaukos reported a net loss of $19.8 million, slightly higher than the previous year's loss. The company continues to focus on advancing its pipeline of novel therapies for chronic eye diseases.
Read more →GKOSGlaukos Receives Permanent J-code for Epioxa™
Glaukos Corporation announced that the U.S. Centers for Medicare and Medicaid Services has assigned a permanent J-code, J2789, for its product Epioxa, effective July 1, 2026. This coding is expected to enhance market access and streamline billing for the treatment of keratoconus. Epioxa represents an innovative, non-invasive alternative to traditional corneal cross-linking procedures, promising improved patient outcomes.
Read more →GKOSGlaukos Announces the Release of its 2025 Sustainability Report
Glaukos has announced the release of its 2025 Sustainability Report. The report details the company's commitment to sustainable practices and environmental responsibility. Further specifics about the contents of the report were not provided in the announcement.
Read more →GKOSGlaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
Glaukos Corporation has announced that it will release its financial results for the first quarter of 2026 after the market closes on April 29. This announcement is part of the company's regular financial reporting schedule. Further details regarding the results will likely be provided during the release.
Read more →GKOSGlaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Glaukos Corporation will present several scientific abstracts at the upcoming 2026 ASCRS Annual Meeting. The event is significant for showcasing advancements in cataract and refractive surgery. Details regarding the specific abstracts and their implications for the field have not been disclosed.
Read more →GKOSInvestor Presentation MARCH 2026 ABOUT GLAUKOS 2 © 2026 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or develo
Glaukos Corporation is making strides in the treatment of chronic eye diseases with promising candidates in clinical trials. Their iLution platform for treating Demodex blepharitis has begun Phase 2 trials, while Epioxa is in line to become the first FDA-approved treatment for keratoconus with an epithelium-on approach. The company shows a solid financial position with a reported gross margin of 85% and no debt, supporting their pipeline growth. However, challenges remain in terms of patient compliance and awareness, as well as market reception for new therapies.
Read more →GKOS▲ +13.5%on this news
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
Glaukos Corporation reported strong financial results for Q4 and full year 2025, with net sales reaching $143.1 million in Q4, a 36% increase year-over-year. However, the company faced a significant operating loss of $139.9 million due to a one-time impairment charge. Despite these challenges, Glaukos remains optimistic about its growth prospects, projecting 2026 net sales between $600 million and $620 million.
Read more →About Glaukos Corporation
Headquarters1 GLAUKOS WAY, ALISO VIEJO, CA, 92656
BIOPHARMAWATCH ELITE PLUS
Trade the next GKOS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime